Amphastar Pharmaceuticals (AMPH) logo

Amphastar Pharmaceuticals (AMPH) stock

Injectable medicines , market cap $1.2B

After-hours Fri
$28.26
+0.04%

Close $28.25 +0.50%

Quality Score
10
Average
In its industry
#28of 273
Checks firing
4of 14
Trending up
From 52-week high
-8.9%
under its best in a year

AMPH's Quality Score rose 1 point on Fri, Nov 20, to 10. It dipped below its 10-day low, then closed back above it.

See AMPH's 14 chart checksSee AMPH's 14 chart checksSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Key facts on AMPH

Key facts on AMPH
Since its 2023 highDown 57% profit $137.5M → $99M a year
Latest filing8-K, Nov 5 Reported its quarterly results

AMPH in the news

Fri Nov 6Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026 SEC filing 4:26 PM ET · PR Newswire and 1 more AMPH closed +3.0% that day.

Outlet counts from the GDELT Project.

AMPH catalysts

Coming up

After its last 4 reports it closed -9.2% on average, higher 2 of 4 times.

8 past catalysts since 2022, with sizes and sources, for Pro members.

Why AMPH scores 10

Averagefor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means

  • +4Chart checks 4 of 14 firing right now, one point each
  • +2Long-term trend above a rising 200-⁠day average, near its 52-⁠week high, down over two years
  • Run-up adds
  • Profit addsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
  • Persistence adds

No effect today: Size, Growth, Dilution, Volatility, Cash flow, News, and Insider trades.

What every line is worth, and the reason behind it, on AMPH and every other stock.Get in free →See the top 3 →Start Pro

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:34 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when AMPH's Quality Score turns up

A free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

How AMPH ranks in Biotech

AMPH is #28 of 273 by Quality Score.

How AMPH ranks in Biotech
RankStockQuality Score
28Amphastar Pharmaceuticals (AMPH) logoAMPHAmphastar Pharmaceuticals10

More in Biotech

When does AMPH report earnings, and what happens after?

Expected to report Thu Feb 25, after the close (in 96 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What AMPH reported on Nov 5, 2026

The quarter

Sales of $207.6M, 8% more than a year ago; a profit of $0.87 a share, from $0.37.

“Changes in net revenues as compared to the third quarter of the prior year were primarily driven by:”

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

Where the quarter's sales came from
LineQ3
2026
Q2
2026
Q3
2025
By region
United Statesup 5.9%$191M92%$172M94%$180M94%

Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 5)

2 more lines, for Pro members.

The outlook

No outlook figures read from this release.

In the company's words

  • “BAQSIMI ® sales increased primarily due to an increase in unit volumes, contributing $7.4 million in sales driven by our continued marketing efforts.”

From its results filing (SEC filing · Nov 5)

2 more sentences, for Pro members.

The numbers

Market value
$1.2B
today
Sales
$746M
up 3.1% on the year
Free cash flow
$139M
last 12 months

Sales grew 16% a year over 5 years, fiscal 2020 to 2025.

Its share count fell 0.4% a year over 5 years.

5 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on AMPH: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-20.9%+4.9%+3.0%
May 7Aug 6Nov 5
ReportedGapReaction5
days
Nov 5, 2026After close+6.4%+3.0%+4.4%
Aug 6, 2026After close+13.5%+4.9%+1.9%
May 7, 2026After close-22.7%-20.9%-28.0%

AMPH closed higher after 2 of its last 4 reports.

All 4 reports, and AMPH's Quality Score going into each

AMPH sales and profit by year

Sales and profit by year

Sales grew in six of the last seven years, to $720M in 2025. It made a profit in seven of the eight years.

AMPH has 4 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on AMPH, and all 14 on every stock.Get in free →See the top 3 →Start Pro

AMPH RSI on Nov 20: 54.2, above its 50-day and 200-day averages

Not scored

RSI 54.2, MACD below signal, above both averages. Not scored.

The deep dive on AMPH

  • What it does and how it makes money3 findingsIt kept 20 cents of each dollar of sales in fiscal 2025: $140M of operating profit on $720M of sales.Annual report, filed Feb 26, 2026
  • Where it stands3 findingsFor Pro members3 findings on where AMPH stands: its cash, debt, and share count, for Pro members
  • What changed in its filings6 findings"On October 30, 2025, a former employee initiated a class action litigation against the Company by filing a complaint for alleged violations of the California Labor Code pertaining to California’s PAGA, wage and hour, and other state laws." (10-Q for the quarter to Sep 30, 2026)SEC filing · Nov 5, 2026A new heading in its "Risk Factors" this year: "If the market for any of our reference brand products significantly declines, sales or potential sales of our generic and biosimilar products and product candidates may suffer and our business would be materially impacted." (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Feb 26, 2026, against the one of Mar 3, 2025McKesson made up 24% of its revenue in fiscal 2025, down from 25% in fiscal 2024.SEC filing · Feb 26, 2026"However, as of September 30, 2026, we experienced a backlog of approximately $12.5 million for various products that are manufactured at our IMS facility related to a temporary slowdown in product releases as we continue the remediation efforts from an FDA warning letter at that facility." (10-Q for the quarter to Sep 30, 2026)SEC filing · Nov 5, 2026
  • Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades AMPH, for Pro members

9 more findings on AMPH, each with its source, for Pro members.

AMPH insider trades

2 insiders sold $477K across 3 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellRong Zhou$239KSenior EVP, Production Centerat $23.94 on Sep 16, filed Sep 17

All 3 insider filings on AMPH from the last six months, for Pro members.

All AMPH insider trades

AMPH trades by Congress and the executive branch

One trade disclosed in the last six months. The newest:

SellDonald Trump$15K to $50KPresident (R)traded May 15, disclosed Jul 1(47 days later)

See what Congress is buying across the market

AMPH's officers and directors

Officers and directors with a Form 4 in the last 12 months.

5 more officers and directors file at AMPH.

See insider trades by person

Which ETFs hold AMPH?

In ETFs: AMPH is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.

1,976 employeesRancho Cucamonga, CAamphastar.com

What Amphastar Pharmaceuticals says it competes with

“We face and will face significant competition for our products and product candidates from pharmaceutical companies that focus on proprietary and generic injectable and inhalation markets such as Pfizer, Inc., BPI Labs, Lupin Pharmaceuticals, Inc., Viatris Inc., Fresenius Kabi USA, Apotex Corp, American Regent Inc., Hikma Pharmaceuticals USA, Inc., Par Pharmaceuticals, Cipla USA Inc., Meitheal Pharmaceuticals, Dr. Reddy’s Laboratories, Inc., Xeris Pharmaceuticals, Medefil Inc., Accord Healthcare, and Teva Pharmaceutical USA Inc. Competition in the generic pharmaceutical industry has increased as producers of branded products have entered the business by creating generic drug subsidiaries, purchasing generic drug companies, or licensing their products to generic manufacturers prior to patent expiration and/or as their patents expire.”

From its annual report, SEC filing · Feb 26, 2026

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on AMPH and every other stock.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would move AMPH's score: 5 things
  • 2 more filings explained, a plain line each
  • Real-⁠time prices, no delay
BreakawayJul 1Donald Trump sold AMPH$15K to $50K, disclosed Jul 1

Alerts are optional.

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: AMPH's Quality Score is 10 (Average), #28 of 273 in Biotech. Insiders sold $477K in the last 6 months (Form 4).

What does AMPH's Quality Score say?

AMPH scores 10 today, which Breakaway calls Average. It is #28 of 273 in Biotech by Quality Score, with 4 of 14 chart checks firing. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is AMPH's Quality Score?

AMPH scores 10 today, which Breakaway calls Average (6 to 10). That is #28 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind AMPH's 10.

Are insiders buying AMPH?

2 insiders sold $477K across 3 filings in the last 6 months. No open-⁠market buys on record. The newest is Rong Zhou, Senior EVP, Production Center, who sold $239K on Sep 16. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.